 Home > Medical News > Latest Medical News > Sage and Bojian SAGE-324 Phase II tremor test reached the primary endpoint

Sage and Bojian SAGE-324 Phase II tremor test reached the primary endpoint

 Last Update: 2021-04-23
 Source: Internet
 Author: User

Tags

mirtazapine 15 mg

benazepril 10 mg

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

CompilationFan Dongdong

A few days ago, Sage Pharmaceuticals and Biogen announced that the Phase 2 KINETIC trial evaluating SAGE-324 in patients with essential tremor (ET) reached the primary endpoint.

The trial mainly evaluated the therapeutic effect of SAGE-324 in a higher dose range.

The results of the test showed that in the KINETIC trial (n=67), compared with placebo, patients received the GABAA receptor positive modulator SAGE-324 for 29 days after treatment, the basic tremor rating scale (TETRAS) performance subscale item 4 In the upper extremity tremor score, the primary endpoint of statistically significant reduction was reached (p=0.

During the 28-day KINETIC trial treatment period, the study patients did not take other ET treatment drugs.

In addition, in terms of safety, the treatment-related emergency adverse events (TEAE) found by patients in the trial so far are generally consistent with the safety of the previous SAGE-324.

SAGE-324 is a research-type oral neuroactive steroid (NAS) GABAA receptor positive allosteric modulator.

At present, Bojian and Sage are satisfied with the latest progress made by SAGE-324, and are planning to advance the next step of SAGE-324 development work.

Reference source:

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.